Your browser doesn't support javascript.
Disparities in COVID-19 infection, hospitalisation and death in people with schizophrenia, bipolar disorder, and major depressive disorder: a cohort study of the UK Biobank.
Hassan, Lamiece; Peek, Niels; Lovell, Karina; Carvalho, Andre F; Solmi, Marco; Stubbs, Brendon; Firth, Joseph.
  • Hassan L; Division of Psychology and Mental Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK.
  • Peek N; Centre for Health Informatics, Division of Informatics, Imaging and Data Sciences, The University of Manchester, Manchester, M13 9PL, UK.
  • Lovell K; NIHR Greater Manchester Patient Safety Translational Research Centre, The University of Manchester, Manchester, UK.
  • Carvalho AF; Division of Nursing, Midwifery and Social Work, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK.
  • Solmi M; IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia.
  • Stubbs B; Psychiatry Department, University of Ottawa, Ottawa, ON, Canada.
  • Firth J; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Mol Psychiatry ; 27(2): 1248-1255, 2022 02.
Article in English | MEDLINE | ID: covidwho-20236617
ABSTRACT
People with severe mental illness (SMI; including schizophrenia/psychosis, bipolar disorder (BD), major depressive disorder (MDD)) experience large disparities in physical health. Emerging evidence suggests this group experiences higher risks of infection and death from COVID-19, although the full extent of these disparities are not yet established. We investigated COVID-19 related infection, hospitalisation and mortality among people with SMI in the UK Biobank (UKB) cohort study. Overall, 447,296 participants from UKB (schizophrenia/psychosis = 1925, BD = 1483 and MDD = 41,448, non-SMI = 402,440) were linked with healthcare and death records. Multivariable logistic regression analysis was used to examine differences in COVID-19 outcomes by diagnosis, controlling for sociodemographic factors and comorbidities. In unadjusted analyses, higher odds of COVID-19 mortality were seen among people with schizophrenia/psychosis (odds ratio [OR] 4.84, 95% confidence interval [CI] 3.00-7.34), BD (OR 3.76, 95% CI 2.00-6.35), and MDD (OR 1.99, 95% CI 1.69-2.33) compared to people with no SMI. Higher odds of infection and hospitalisation were also seen across all SMI groups, particularly among people with schizophrenia/psychosis (OR 1.61, 95% CI 1.32-1.96; OR 3.47, 95% CI 2.47-4.72) and BD (OR 1.48, 95% CI 1.16-1.85; OR 3.31, 95% CI 2.22-4.73). In fully adjusted models, mortality and hospitalisation odds remained significantly higher among all SMI groups, though infection odds remained significantly higher only for MDD. People with schizophrenia/psychosis, BD and MDD have higher risks of COVID-19 infection, hospitalisation and mortality. Only a proportion of these disparities were accounted for by pre-existing demographic characteristics or comorbidities. Vaccination and preventive measures should be prioritised in these particularly vulnerable groups.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Schizophrenia / Bipolar Disorder / Depressive Disorder, Major / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: Mol Psychiatry Journal subject: Molecular Biology / Psychiatry Year: 2022 Document Type: Article Affiliation country: S41380-021-01344-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Schizophrenia / Bipolar Disorder / Depressive Disorder, Major / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: Mol Psychiatry Journal subject: Molecular Biology / Psychiatry Year: 2022 Document Type: Article Affiliation country: S41380-021-01344-2